Cost-effectiveness of Triple Therapy with Telaprevir for Chronic Hepatitis C Virus Patients in Germany
**Background:** About 400,000-500,000 people are infected with hepatitis C in Germany. Long-term consequences are the development of liver cirrhosis and hepatocellular carcinoma. The introduction of first generation protease inhibitors has significantly improved the treatment of hepatitis C genotype...
Saved in:
Main Authors: | Jona T. Stahmeyer, Svenja Schauer, Siegbert Rossol, Hans Heinrich Wedemeyer, Daniel Wirth, Florence Bianic, Christian Krauth |
---|---|
Format: | Article |
Language: | English |
Published: |
Columbia Data Analytics, LLC
2013-12-01
|
Series: | Journal of Health Economics and Outcomes Research |
Online Access: | https://jheor.org/article/9870-cost-effectiveness-of-triple-therapy-with-telaprevir-for-chronic-hepatitis-c-virus-patients-in-germany |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Real-Life Experiences with Telaprevir in the Treatment of Chronic Genotype 1 Hepatitis C — The TEPS Study
by: T. Berg, et al.
Published: (2019-01-01) -
Telaprevir in treatment of chronic hepatitis C: safety issues
by: T. M. Ignatova
Published: (2012-07-01) -
Telaprevir Activity is unaffected by the Q80K Polymorphism in Hepatitis C virus Genotype 1a
by: Stephen Shafran
Published: (2014-01-01) -
Treatment Outcomes with Telaprevir-Based Therapy for HIV/Hepatitis C Coinfected Patients are Comparable with Hepatitis C Monoinfected Patients
by: Conar R O’Neil, et al.
Published: (2015-01-01) -
Telaprevir: options of application in separate patient groups
by: M. V. Mayevskaya, et al.
Published: (2013-10-01)